Donald Trump has laid out a fresh tariff roadmap for generic medicines entering the United States, giving drugmakers a fixed window to shift factories onshore before costs rise sharply.
Zero tariff now, steep hikes later
Starting August 1st, 2026, generic drugs imported into the US will continue to carry a zero percent tariff, exactly as they do today. That zero rate holds for two years. Once the two-year window closes, the tariff jumps to 100 percent for a further one-year stretch, and after that it rises again to 200 percent.
Why the timeline exists
Trump said the staged tariff hikes are designed to reshore generic pharmaceutical production back into the United States. Companies get the two-year grace period to build plants and equipment domestically; those that choose not to are the ones who will face the rising tariff as a penalty. Trump framed the entire policy as protection for the American public.
Branded and patented drugs untouched
The existing tariff approach for patented, branded, or innovative drugs is not changing. Trump described that policy as already working well and said it will remain exactly as is, with the new tariff schedule applying only to generic drugs.
What Trump said
Trump wrote that "the objective of this policy is to protect the people of the United States," and added that pharmaceutical facilities are being built across the country at an unprecedented pace.
What comes next
Based on the dates Trump set out, the 100 percent tariff would begin around August 2028, with the 200 percent rate following roughly a year later.
